{"prompt": "['Product: MK-3475', '3', 'Protocol/Amendment No.: 604-09', '4.2.3.7 Future Biomedical Research', '32', '4.3', 'Benefit/Risk', '32', '5.0', 'METHODOLOGY', '33', '5.1', 'Entry Criteria', '33', '5.1.1', 'Diagnosis/Condition for Entry into the Trial', '33', '5.1.2', 'Subject Inclusion Criteria', '33', '5.1.3', 'Subject Exclusion Criteria', '35', '5.2', 'Trial Treatment(s)', '38', '5.2.1 Dose Selection/Modification', '38', '5.2.1.1 Dose Selection (Preparation)', '38', '5.2.1.2', 'Dose Modification', '39', '5.2.1.2.1 Pembrolizumab', '40', '5.2.1.2.2', 'Chemotherapeutic agents (etoposide/platinum)', '48', '5.2.2 Timing of Dose Administration', '51', '5.2.2.1 Pembrolizumab (or Saline Placebo)', '52', '5.2.2.2 Chemotherapy', '52', '5.2.2.2.1 Carboplatin', '52', '5.2.2.2.2', 'Cisplatin', '53', '5.2.2.2.3', 'Etoposide', '53', '5.2.3 Trial Blinding', '53', '5.3', 'Randomization', '54', '5.4', 'Stratification', '54', '5.5', 'Concomitant Medications/Vaccinations (Allowed & Prohibited)', '54', '5.5.1 Acceptable Concomitant Medications', '54', '5.5.2 Prohibited/Restricted Concomitant Medications', '55', '5.6', 'Rescue Medications & Supportive Care', '56', '5.6.1', 'Supportive Care Guidelines', '56', '5.7', 'Diet/Activity/Other Considerations', '57', '5.7.1', 'Diet', '57', '5.7.2 Contraception', '57', '5.7.3', 'Use in Nursing Women', '59', '5.8', 'Subject Withdrawal/Discontinuation Criteria', '59', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '4', 'Protocol/Amendment No.: 604-09', '5.8.1', 'Discontinuation of Treatment', '59', '5.8.2 Withdrawal from the Trial', '61', '5.9', 'Subject Replacement Strategy', '61', '5.10', 'Beginning and End of the Trial', '61', '5.11', 'Clinical Criteria for Early Trial Termination', '61', '6.0', 'TRIAL FLOW CHART', '62', '6.1', 'Initial Treatment Phase', '62', '6.2', 'Second Course Treatment Phase', '68', '7.0', 'TRIAL PROCEDURES', '71', '7.1', 'Trial Procedures', '71', '7.1.1 Administrative Procedures', '71', '7.1.1.1', 'Informed Consent', '71', '7.1.1.1.1', 'General Informed Consent', '71', '7.1.1.1.2 Consent and Collection of Specimens for Future Biomedical', 'Research', '72', '7.1.1.2 Inclusion/Exclusion Criteria', '72', '7.1.1.3', 'Subject Identification Card', '72', '7.1.1.4 Medical History', '72', '7.1.1.5 Prior and Concomitant Medications Review', '72', '7.1.1.5.1 Prior Medications', '72', '7.1.1.5.2 Concomitant Medications', '73', '7.1.1.6 Assignment of Screening Number', '73', '7.1.1.7 Assignment of Treatment/Randomization Number', '73', '7.1.1.8 Trial Compliance (Medication/Diet/Activity/Other)', '73', '7.1.2 Clinical Procedures/Assessments', '73', '7.1.2.1', 'Adverse Event Monitoring', '73', '7.1.2.2', 'Physical Examination', '74', '7.1.2.2.1', 'Full Physical Examination', '74', '7.1.2.2.2 Directed Physical Examination', '74', '7.1.2.3', 'Vital Signs', '74', '7.1.2.4', '12-Lead Electrocardiogram', '74', '7.1.2.5', 'Eastern Cooperative Oncology Group Performance Status', '74', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}